Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance to therapy remains a serious clinical problem. To study the underlying mechanisms, we induced therapy resistance in pati...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	JNCI : Journal of the National Cancer Institute Ročník 108; číslo 11
Hlavní autoři:	Ter Brugge, Petra, Kristel, Petra, van der Burg, Eline, Boon, Ute, de Maaker, Michiel, Lips, Esther, Mulder, Lennart, de Ruiter, Julian, Moutinho, Catia, Gevensleben, Heidrun, Marangoni, Elisabetta, Majewski, Ian, Józwiak, Katarzyna, Kloosterman, Wigard, van Roosmalen, Markus, Duran, Karen, Hogervorst, Frans, Turner, Nick, Esteller, Manel, Cuppen, Edwin, Wesseling, Jelle, Jonkers, Jos
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.11.2016
Témata:	Animals Antineoplastic Agents - therapeutic use BRCA1 Protein - deficiency Cisplatin - therapeutic use DNA Methylation Drug Resistance, Neoplasm - genetics Female Gene Expression Gene Fusion Genes, BRCA1 Humans Melphalan - therapeutic use Mice Mutation Neoplasm Transplantation Nimustine - therapeutic use Phthalazines - therapeutic use Piperazines - therapeutic use Promoter Regions, Genetic Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics
ISSN:	1460-2105
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!